First enrolment for Pharmaxis Aridol COPD study
16 September, 2005 by Helen SchullerDrug developer Pharmaxis (ASX:PXS) has enrolled its first patient for the phase II clinical trial to assess the ability of Aridol to predict the usefulness of inhaled corticosteroids as a treatment of chronic obstructive pulmonary disease (COPD).
Novogen drug reduces cardiovascular risk, subsidiary to list on NASDAQ
14 September, 2005 by Ruth BeranBiopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial.
Grunt work over, Starpharma looks to VivaGel future
09 September, 2005 by Helen SchullerContinuing development of its lead product VivaGel has boosted Starpharma's (ASX:SPL) 2004-05 losses to $5.5 million, up 38 per cent from the previous year.
Indian orders for Panbio JE diagnostic
07 September, 2005 by Ruth BeranMedical diagnostics company Panbio's (ASX:PBO) new assay for Japanese encephalitis (JE), released for sale just two days ago, has received immediate interest and has been shipped to India where a JE outbreak has resulted in 1145 reported cases, including 296 deaths.
Progen flush as PI-88 trials continue
06 September, 2005 by Helen SchullerBrisbane cancer drug developer Progen Industries (ASX:PGL) has reported a strong cash position of AUD$23.43 million, up 64 per cent on last year for the year ended 30 June 2005, as it continues to trial its lead anti-cancer compound.
Solbec's Coramsine found safe and tolerable
05 September, 2005 by Ruth BeranSolbec Pharmaceuticals' (ASX:SBP) devil's apple-derived drug Coramsine (SBP002) has met the primary endpoint of safety and tolerability for the two-hour infusion cohort of its single agent phase I clinical trial for advanced solid tumours.
Bionomics allowed US epilepsy gene patent
02 September, 2005 by Ruth BeranSouth Australian genomics company Bionomics (ASX:BNO) has received a notice of allowance for a US patent, forming part of the company's patent portfolio covering a diagnostic test for severe forms of childhood epilepsy.
Peter Mac tests tumour-cell zapper
02 September, 2005 by Graeme O'NeillResearchers at Melbourne's Peter MacCallum Cancer Centre have begun testing a high-precision, antibody-mediated system to deliver short-range radionuclides to cancerous cells.
Financial results in brief
02 September, 2005 by Staff WritersCancer therapy developer Meditech (ASX:MTR) has received an AusIndustry Commercial Ready Grant worth $2.988 million over the next three years towards the development and commercialisation of HyCAMP, its lead anti-cancer product which is in phase II clinical testing. Meditech has also reported a half year loss of $1.68 million and a cash balance of $3.4 million.
Peplin cancer drug in US dose-escalation trial
01 September, 2005 by Graeme O'NeillBrisbane oncology-drug developer Peplin (ASX:PEP) has begun a phase IIa dose-escalation trial of its PEP005 lead product for pre-cancerous skin lesions, or actinic keratoses (AKs) caused by ultraviolet radiation in sunlight.
Clinical Trials Victoria unveils new name, CEO
30 August, 2005 by Ruth BeranNucleus Network, the new umbrella name for Clinical Trials Victoria (CTV), the Centre for Clinical Studies (CCS) and its member alliances, was launched today at the organisation's facility, located adjacent to Melbourne's Alfred Hospital -- three hours after a 12-patient clinical trial finished in the same room
Amrad maintains strong cash position
29 August, 2005 by Helen SchullerAmrad (ASX:AML) has reported a healthy cash position of AUD$51.7 million and an operating loss of AUD$1.622 million for the year ended 30 June 2005, down from $3.523 million last year.
New movement laboratory launched
26 August, 2005 by Ruth BeranAustin Health's new movement laboratory has been opened at the Royal Talbot Rehabilitation Centre in Kew, Melbourne to provide a clinical movement analysis service to assist people with disabilities to become more independent.
WA team IDs leukaemia key
24 August, 2005 by Graeme O'NeillResearchers at the Western Australian Institute for Medical Research (WAIMR) have identified a key gene in acute myeloid leukaemia (AML) that could serve both as a prognostic marker and a target for new drugs to treat the disease.
Astop Biohealth plans ASX listing
22 August, 2005 by Ruth BeranAstop Biohealth, an unlisted natural medicines company established in 2001 and chaired by Perth entrepreneur Kevin Parry, is planning to list on the ASX before the end of the year.
